Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.
Iula R, De Novellis D, Trastulli F, Della Pepa R, Fontana R, Carobene A, Di Perna M, D'Ambrosio A, Romano M, Leone A, De Fazio L, Fiumarella A, Gaeta G, Marafioti V, Barbato S, Palmieri S, Rocco S, Serio B, Califano C, Pane F, Ferrara F, Giudice V, Selleri C, Catalano L. Iula R, et al. Among authors: catalano l. Front Oncol. 2022 Nov 15;12:1026251. doi: 10.3389/fonc.2022.1026251. eCollection 2022. Front Oncol. 2022. PMID: 36457484 Free PMC article.
Safety and comfort of domestic bortezomib injection in real-life experience.
Cerchione C, Nappi D, Pareto AE, Di Perna M, Zacheo I, Picardi M, Pane F, Catalano L. Cerchione C, et al. Among authors: catalano l. Support Care Cancer. 2018 Sep;26(9):3111-3116. doi: 10.1007/s00520-018-4155-8. Epub 2018 Mar 24. Support Care Cancer. 2018. PMID: 29574618
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.
Palmieri S, Rocco S, Vitagliano O, Catalano L, Cerchione C, Vincelli ID, Scopelliti A, Gentile M, Farina G, Barone M, Gagliardi A, Esposito D, Arcamone M, Amico V, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F. Palmieri S, et al. Among authors: catalano l. Ann Hematol. 2020 Dec;99(12):2903-2909. doi: 10.1007/s00277-020-04158-4. Epub 2020 Jun 25. Ann Hematol. 2020. PMID: 32583088
Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
Cerchione C, De Renzo A, Di Perna M, Della Pepa R, Pugliese N, Catalano L, Pane F, Picardi M. Cerchione C, et al. Among authors: catalano l. Support Care Cancer. 2017 Mar;25(3):839-845. doi: 10.1007/s00520-016-3468-8. Epub 2016 Nov 3. Support Care Cancer. 2017. PMID: 27812763 Free PMC article.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Vincelli ID, Martino EA, Vigna E, Bruzzese A, Mendicino F, Botta C, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Falcone AP, Cangialosi C, Reddiconto G, Farina G, Barone M, Rizzello I, Iaccino E, Mimmi S, Curci P, Gamberi B, Musto P, De Stefano V, Musso M, Petrucci MT, Offidani M, Di Raimondo F, Boccadoro M, Cavo M, Neri A, Gentile M. Morabito F, et al. Among authors: catalano l. Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376. eCollection 2022. Front Oncol. 2022. PMID: 35924160 Free PMC article.
359 results